Clinical Trial Update: Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 early trial (SATFRE) evaluating sirolomus as an adjuvant treatment for focal refractory epilepsy is currently recruiting at Xuanwu Hospital in Beijing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Epilepsy

Drugs mentioned

• Sirolomus (sirolomus)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Epilepsy, Drug Resistant | EARLY_Phase 1 | Status: RECRUITING